Double‐blind, randomized, 8‐week multicenter study of the efficacy and safety of STW 5‐II versus placebo in functional dyspepsia
Article in JGH Open (May 2024)
The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.
Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double‐blind, placebo control clinical trial
Article in Neurogastroenterology & Motility (February 2024)
Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis
Article in Digestion (January 2024)